Nxera Pharma Co., Ltd. (4565.T) JPX
958.00
-50(-4.96%)
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Nxera Pharma Co., Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
387
First IPO Date
July 29, 2004
Key Executives
| Name | Title | Pay | Year Born |
| Candelle Chong | Executive Officer, Chief Executive Officer Office & Chief of Staff | 87M | 1989 |
| Chris Cargill | Representative Executive Officer, President, CEO & Chairman | 150M | 1984 |
| Hironoshin Nomura | Executive Officer & Chief Financial Officer | 68M | 1983 |
| Kieran Johnson | Executive Officer & Chief Accounting Officer | 83M | 1969 |
| Shinichi Tamura | Founder | 233M | 1949 |
| Kazuhiko Yoshizumi | Executive Officer & Chief Compliance Officer | 0 | 1954 |
| Shinya Tsuzuki | Head of Investor Relations | 0 | N/A |
| Toshihiro Maeda | President of Nxera Pharma Japan & Chief Operating Officer | 0 | 1979 |
| Mariko Nakafuji | Executive Vice President & Chief Legal Officer | 0 | N/A |
| Stacey Southall | Associate Director & Head of Biophysics | 0 | N/A |
| Patrik Foerch | Chief Scientific Officer, President of Nxera Pharma UK & Director | 0 | N/A |
| Patrick Branch | Head of Business Development for Japan and the APAC region | 0 | N/A |
| Shinichiro Nishishita | Vice President of Investor Relations & Head of Regulatory Disclosures | 0 | N/A |
Description
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
